ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Sep 30, 2025. Filed Nov 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Nov 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 2. PROPERTIES
The following table summarizes the Company’s leased facilities as of November 19, 2025.
| Approximate Square Footage | Primary Use | LeaseExpiration | Remaining Lease Term (year) | |
|---|---|---|---|---|
| Pasadena, California | 49,000 | Corporate Headquarters | April 2027 | 1.5 |
| Madison, Wisconsin | 110,956 | Research Facility | September 2031 | 5.9 |
| San Diego, California | 144,000 | Research and Office Facility | April 2038 | 12.5 |
The Company owns land in the Verona Technology Park in Verona, Wisconsin, which has been developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company’s manufacturing process development and analytical activities. The Company completed the build out of one of its laboratory and office facilities during the first quarter of fiscal year 2024 and substantially completed the build out of its manufacturing facility during the first quarter of fiscal year 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.